Bridge Biotherapeutics Past Earnings Performance
Past criteria checks 0/6
Bridge Biotherapeutics's earnings have been declining at an average annual rate of -31.6%, while the Biotechs industry saw earnings growing at 9.2% annually. Revenues have been declining at an average rate of 66.6% per year.
Key information
-31.6%
Earnings growth rate
-4.5%
EPS growth rate
| Biotechs Industry Growth | 11.7% |
| Revenue growth rate | -66.6% |
| Return on equity | -215.3% |
| Net Margin | -42,321.0% |
| Last Earnings Update | 31 Dec 2023 |
Recent past performance updates
Revenue & Expenses BreakdownBeta
How Bridge Biotherapeutics makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 31 Dec 23 | 100 | -42,321 | 13,477 | 25,299 |
| 30 Sep 23 | 2,151 | -36,101 | 12,970 | 25,912 |
| 30 Jun 23 | 2,296 | -38,957 | 13,313 | 28,749 |
| 31 Mar 23 | 2,857 | -41,496 | 13,280 | 31,690 |
| 31 Dec 22 | 3,024 | -41,700 | 13,033 | 32,093 |
| 30 Sep 22 | 1,422 | -42,301 | 15,861 | 27,253 |
| 30 Jun 22 | 1,501 | -37,645 | 14,072 | 24,439 |
| 31 Mar 22 | 2,091 | -31,154 | 12,502 | 20,199 |
| 31 Dec 21 | 1,924 | -26,278 | 10,304 | 17,517 |
| 30 Sep 21 | 3,524 | -23,145 | 6,885 | 16,961 |
| 30 Jun 21 | 4,570 | -21,372 | 6,441 | 15,368 |
| 31 Mar 21 | 3,656 | -17,988 | 6,213 | 11,068 |
| 31 Dec 20 | 6,340 | -19,232 | 5,649 | 12,373 |
| 30 Sep 20 | 19,329 | -11,487 | -11,801 | 24,468 |
| 30 Jun 20 | 61,304 | -1,238 | -2,903 | 21,366 |
| 31 Mar 20 | 60,968 | -4,201 | 1,922 | 21,087 |
| 31 Dec 19 | 58,283 | 1,325 | 6,116 | 15,190 |
| 30 Sep 19 | 43,245 | -11,892 | 22,594 | 4,096 |
Quality Earnings: A288330 is currently unprofitable.
Growing Profit Margin: A288330 is currently unprofitable.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: A288330 is unprofitable, and losses have increased over the past 5 years at a rate of 31.6% per year.
Accelerating Growth: Unable to compare A288330's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: A288330 is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (28.8%).
Return on Equity
High ROE: A288330 has a negative Return on Equity (-215.29%), as it is currently unprofitable.